significantly shorter progression-free survival (median, 21 months) than patients whose samples at diagnosis had low Ang-2 levels (median, 146 months) (P ¼ 0.002). Then, Ang-2 levels were associated with sex (P ¼ 0.003), being male 26 out of 32 (81.3%) CLL patients with high levels of Ang-2. Finally, there was a trend toward higher percentage of circulating lymphocytes (P ¼ 0.053), lower platelet count (P ¼ 0.061) and higher serum level of b2-microglobulin (P ¼ 0.057) in patients expressing elevated Ang-2 (Table 1) .
In order to define the cellular population expressing Ang-2 in PB and BM, we purified CD19 þ and CD19 À fractions from PBMCs of 10 CLL patients (4 UM-CLL with high Ang-2 mRNA level and 6 M-CLL with low Ang-2 mRNA level, as previously assessed), selected for the availability of BM biopsies for immunohistochemical study. Leukemic CD19 þ cells displayed Ang-2 transcript levels concordant with the correspondent unpurified samples (both high and low expressing), whereas bystander CD19 À cells did not reveal appreciable expression of Ang-2 in all 10 cases (median, 0.68). These results together with the capacity of Ang-2 secretion into the culture supernatant observed in three CLL cases by Hü ttmann et al. provide evidence that Ang-2 is expressed by circulating leukemic cells and not by bystander not malignant cells. In addition, in the CLL marrow microenvironment, immunohistochemical staining for Ang-2 protein showed that infiltrating CLL cells from 6 mutated cases were all negative, whereas CLL cells from 4 unmutated cases were uniformly positive, confirming in BM the observed Ang-2 mRNA expression measured in the circulating CLL fraction ( Figure S1 ). Finally, we compared Ang-2 mRNA expression of CD19 þ purified cells from 10 CLL and from 9 normal controls. The results confirmed the abnormal expression of Ang-2 in UM-CLL subsets (median, normal control 4.6 vs UM-CLL 3146) and the low expression in M-CLL subset (median, M-CLL 0.072).
Our results regarding the adverse prognostic significance of high expression of Ang-2 by CLL cells are substantially in keeping with Hü ttmann et al. Importantly, in our series, CLL patients expressing at diagnosis high levels of Ang-2 usually had more advanced clinical stage and a higher percentage of CD38 þ cells, had unmutated immunoglobulin status and unfavorable cytogenetics and had a shorter progression-free survival. These associations support the idea of the involvement of Ang-2 in the mechanisms of CLL disease progression. In addition, both circulating and BM-infiltrating Ig-unmutated CLL B-cells are able to express higher levels of Ang-2 than Ig-mutated CLL and normal B cells, suggesting the presence of an intrinsic defect in Ang-2 expression that could be pathogenetically relevant in CLL marrow microenvironment and could be involved in the differential clinical behavior of Ig-mutated and Ig-unmutated CLL cases. R Maffei 1, 5 , R Marasca 1, 5 Chronic lymphocytic leukaemia (CLL) is the most common form of leukaemia accounting for around 30% of all cases. Inherited predisposition to CLL is now well established, with epidemiological studies showing 3-7-fold elevations of risk in first-degree relatives of CLL cases. 1 Although no gene, which when mutated in the germline, has been shown to unambiguously confer susceptibility to the disease, we have, recently localized a disease locus on chromosome 11p11. 2 Two genes SPI1 (encoding PU.1) and MADD (Mendelian inheritance in man: 165170 and 603584) localize to 11p11 and represent preeminent candidate susceptibility genes a priori.
PU.1 has recently attracted considerable attention as a major player in haematoproliferative differentiation. 3 PU.1, a member of the ETS family of transcription factors, is upregulated during normal haematopoiesis, but specifically in mature myeloid and B cells influencing the expression of a number of key proteins, including colony-stimulating factor and immunoglobulin subunits (overviewed in Okuno et al. 4 ) In mice disruption of both alleles of SPI1 results in profound defects in the development of both lymphoid and myeloid cell lineages. Moreover, loss of SPI1 expression has been shown to cause acute myeloid leukaemia (AML) in mice, and heterozygous mutations have been documented in AML patients. 5 MADD participates in the signalling pathways between TNFR1 and MAP kinase enzymes. 6 The activation of MAP kinases constitutes an important pathway in the cellular response to TNF, and antisense abrogation of MADD expression induces apoptosis of leukaemia cells and alters the transcription of apoptotic and cell cycle genes. 7 Furthermore, expression of MADD, particularly of its death domain, stimulates the basal and TNF-induced activation of ERK. Collectively, these data provide a strong rationale for considering SPI1 and MADD as potential CLL susceptibility genes.
To evaluate directly whether sequence variants of SPI1 or MADD might be rare, high-risk CLL susceptibility alleles, we have screened the coding sequence and intron-exon boundaries of both genes in a series of 75 CLL families. For PU.1 we have also extensively evaluated an upstream regulatory element (URE) located À14.5 kb proximal to the SPI1 promoter, which has been shown to influence the dynamic expression of the protein required for normal lymphoid development and tumour suppression. 3 To empower our analysis, all of the affected individuals screened were from CLL families in which segregation of disease was compatible with linkage to chromosome 11p11.
Peripheral blood samples from 75 unrelated CLL patients (38 men and 37 women) with a family history of CLL were ascertained through European haematologists participating in the International CLL linkage consortium. The mean age of diagnosis in patients was 59 years (range 35-81 years) with 39 being aged p60 years at diagnosis. Patient selection was based on standard haematological and immunological criteria 8 and evidence of genetic linkage to chromosome 11p on the basis of previously generated data. 2 No separation of tumour B cells from other cells was undertaken before peripheral blood DNA extraction; however, matched mouthwash samples were also collected and served as a source of constitutional DNA to validate sequence changes identified as being germline in origin. Peripheral blood samples were also obtained from 188 healthy British Caucasians (94 men and 94 women, average age 59 years) with no personal history of malignancy and who served as a source of controls. DNA from all peripheral blood samples was extracted using a standard sucrose-lysis salting-out method. Germline DNA from mouthwashes was obtained by using QIAamp DNA mini columns (Qiagen, Valencia, CA, USA) and by following the manufacturer's protocol. All biological samples were obtained from patients and controls with informed consent and ethical review board approval in strict accordance with the tenets of the declaration of Helsinki.
A search for mutations in the coding regions and splice sites of the MADD (isoform d encoded by transcript variant 4, 35 exons) and SPI1 genes (five exons) and the previously described À14.5 kb conserved URE region of SPI1 3 was performed by bidirectionally sequencing amplified PCR fragments using BigDye Terminator chemistry implemented on an ABI 3730xl sequencer (Applied Biosystems, Foster City, CA, USA). PCR primers were designed using Primer 3 software to the chromosome 11 genome contig sequence (NT_009237, NCBI Build 36.1) and are available upon request. Primers for the coding region of each gene were designed to facilitate investigation of all intron-exon boundaries to exclude splice junction mutations. Resultant traces were aligned and compared to the gene consensus sequences (NT_009237: MADD region 46078200-46138823, SPI1 region 46170982-46212150) obtained from the human genome database (http://www.ncbi.nlm.nih.gov) using the software package Mutation Surveyor (Version 3.0; SoftGenetics, State College, PA, USA). Evaluation of the previously identified Letters to the Editor functional URE located -14.5 kb to the SPI1 promoter was undertaken by PCR amplification and direct sequencing of the two conserved regions identified by Okuno et al.
(Figure 1a).
Mutational analysis of the coding region of MADD revealed the presence of eight exonic variants in the CLL cases (Table1 and Figure 1b) , including five non-synonymous changes and one leading to the creation of a novel stop codon R766X in exon 13. Four of the eight exonic variants have been previously documented as polymorphisms in dbSNP (rs326214, rs326217, rs1051006 and rs3736101). All variants were found in comparable frequencies in our cases and controls including the novel R766X variant (T MAF ¼ 0.06) ( Table 1) . No homozygous individuals were identified for the 766X truncating allele in either cases or controls. R776X resides in an area of the MADD gene not translated in two (SV2 and DENN-SV3) of the four known isoforms (IG20, MADD/DENN, SV2 and DENN-SV3) of MADD. 9 It is entirely plausible that the 776X variant would lead to the early truncation of the exogenous IG20 and MADD/ DENN splice variants with concomitant loss of the death domain of the expressed protein (Figure 1b) . Such a notion is accordant with the functional studies reported by Schievella et al., 6 which showed that deletion of the C-terminal death domain results in loss of function of the MADD protein.
Possession of the 766X allele may not, however, have functional consequences because of the ability to process wild-type SV2 and DENN-SV3 cDNAs from alternative splicing. Although splice variants of MADD have been reported to differentially affect TNF-a-induced, caspase-mediated apoptosis, 9 it seems unlikely that any of the sequence changes we identified underlie susceptibility to CLL as they were present in controls at similar frequencies. Irrespective of these findings with respect to familial CLL, the observation that a truncating variant of MADD is not uncommon in the general population suggests that if sequence changes in MADD impact on risk of any malignancy they may do so through differential expression of isoforms.
No exonic changes were identified in the coding region of SPI1 in our series of CLL cases. Extensive mutational analysis of the -14.5 kb URE identified eight sequence variants, of which five mapped to either of the two previously identified regions of high sequence homology in mammals (Figure 1a) . Four insertion/deletion variants were identified, three of which (214InsC, 680_730del, 744_746_delGGA) were located within either of the homologous regions. Of the eight SPI1 URE variants identified, five were found in our series of 188 controls, with none affecting the known TCF factor or PU.1 binding sites.
Our analyses are the first to report a large mutation screen of SPI1 and MADD in CLL. We did not identify any clearly pathogenic SPI1 and MADD gene mutations in our CLL pedigrees. On the basis of the number of individuals we have screened for constitutive mutations, we can, even assuming a conservative detection rate of 90%, conclude with B90%, probability that germline variation in these genes will not account for more than 3% of familial CLL. Our data therefore strongly indicate that germline mutations in these genes do not confer a high risk of CLL and do not make a major contribution to the familial risk of the disease. As we have screened only familial cases, we cannot exclude the possibility that some sequence variants may be associated with low penetrance susceptibility. Evaluation of this hypothesis will require additional studies comparing the frequency of sequence variants in a much larger series of ethnically matched CLL cases and healthy controls. Variants that were only identified in controls and were not present in the CLL samples.
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The causative molecular event in chronic myeloid leukemia (CML) is the genetic transposition of ABL and BCR sequences to form a BCR-ABL fusion gene, leading to the expression of a constitutively active tyrosine kinase. 1 Inhibition of BCR-ABL Kinase activity with the small molecule drug imatinib (IM) results in a rapid hematologic response and has revolutionized the therapy of CML patients. 2 Resistance to IM is a growing clinical problem, resulting in many cases from the acquisition of mutations in the BCR-ABL kinase domain (KD). Detection of specific mutations directs changes in management such as the use of new tyrosine kinase inhibitors or stem cell transplantation. For this reason, periodic genotyping of the BCR-ABL KD to screen for drug-resistant mutations may play an important role in the management of CML patients. 3 We developed a sensitive and quantitative high-throughput assay using SEQUENOM MassARRAY system that enables fast and reliable detection of mutations in the BCR-ABL KD.
One hundred and two cDNA samples obtained from peripheral blood of 40 patients diagnosed with Philadelphiapositive CML were analyzed, 26 patients had chronic phase, 10 accelerated and four blast crisis CML. Twenty-nine patients were IM resistant (mean disease duration 47 months) and 11 were IM intolerant (mean disease duration 28 months).
MassARRAY genotyping was carried out using a chip-based matrix-assisted laser desorption-time-of-flight mass spectrometer (Figure 1a ) (Sequenom, San Diego, CA, USA). Multiplex SNP assays were designed (Supplementary File 1 online) (Mass-ARRAY assay design v 3.0, Sequenom) for 27 previously reported different mutations that confer IM resistance ( Table 1) . The reactions were carried out according to the manufacturer's instructions 4 ( Figure 1b) . The BCR-ABL KD mutational status was also determined by direct sequencing as previously C1308T  T315I  2  C1106G  L248V  16  C1308A  T315N  3   a   G1113A  G250E  17   a   C1315G  F317L  4  G1112A  G250R  18  T1392C  M343T  5  G1120C  Q252H  19  T1416C  M351T  6  G1120T  Q252H  20   a   T1439G  F359V  7   a   T1121C  Y253H  21  T1440G  F359C  8  A1122T  Y253F  22  G1499A  V379I  9  G1127A  E255K  23  T1508C  F382L  10  A1128T  E255V  24   a   T1523A  L387M  11  A1191G  D276G  25  G1525C  L387F  12  A1194G  T277A  26  A1551C  H396P  13  T1230C  V289A  27  A1551G  H396R  14  T1295C  F311L a Detected mutations.
b Mutation was identified in two different patients.

